NCT Number: NCT06624501
Integrated Discovery and Development of Innovative TB Diagnostics
The long term goal of this project is to provide information critical to the development and use of a low-cost, point-of-care, rapid, simple, and highly accurate diagnostic tool that can help clinicians make a microbiological diagnosis in children who present with signs and symptoms suggestive of TB.
Specific aim 1: To identify the types of patient samples from which to best detect Mtb DNA in children with TB. We propose to obtain serial samples of sputum, blood, stool, and gastric and nasopharyngeal secretions from children with symptomatic TB and to use molecular methods to characterize the distribution of Mtb in these samples. The results of this study will allow us to identify the most promising sampling strategies for diagnosis of TB in children so that optimization of these easily-accessible samples for detection of Mtb nucleic acids can be addressed.
Specific aim 2: To determine whether cell free Mtb DNA can be detected in plasma and urine samples of children and adults with TB and to describe the host-related factors that alter the sensitivity of this assay. We propose to test serial urine and plasma samples for Mtb DNA fragments in two groups: (1) children with symptoms of TB and (2) adults with TB. Here, we will optimize sample volume sizes and of state-of-the-art sequencing tools to improve DNA recovery and detection. This study will help identify optimal samples and strategies for the non-invasive diagnosis of Mtb using urine.
Secondary aim: To create a bank of archived specimens for (1) optimization of Mtb DNA purification, extraction, and (2) use in future pediatric TB diagnostic research.
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Observational
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for aim 1:
Children must meet all of the following criteria at the time of enrollment to participate:
- Age < 15 years;
- Presents to a participating health center;
- Meets the Criteria for Enrollment of Children Into TB Diagnostic Evaluation Studies
- Has a history of contact with an adult with TB disease; and
- A guardian provides informed consent for minor to participate and, if age 8 to 14 years, the minor also provides assent.
Inclusion criteria
for aim 2:
Inclusion criteria
for children who participate in Aim 2 will be the same as for those for Aim 1. Adults who participate in Aim 2 must meet all of the following criteria at the time of enrollment to participate.
- Age ≥ 18 years;
- Presents to a participating health center;
- Is diagnosed with incident pulmonary TB;
- Has sputum smear microscopy results;
- Has not yet initiated tuberculosis treatment; and
- Is willing to receive a rapid HIV test.
Exclusion criteria
-
Treatment and study plan
Primary outcomes
-
Sensitivity for detection of Mtb, by sample type
Time frame: Baseline
For each type of biologic specimen, the proportion of samples in which Mtb could be isolated by DNA detection methods (sensitivity) relative to the standard of care (a combination of sputum smear, sputum culture, signs and symptoms).
Sponsors and collaborators
Lead sponsor
Harvard University Faculty of Medicine
Other
Registry information
Acronym: (CETR)
Important dates
- Study start
- 2015
- Primary completion
- 2018
- Study completion
- 2020
- First posted
- Oct 3, 2024
- Registry last updated
- Oct 3, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary Tuberculosis
NCT04995406
Actinomycetales Infections, Bacterial Infections
Cape Town, South Africa
View Trial DetailsPOC Strategies to Improve TB Care in Advanced HIV Disease
NCT04122404
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Accra, Ghana
View Trial DetailsTuBerculosis Viability Interregional Study and Agreement on Biological Tests
NCT04968886
Actinomycetales Infections, Bacterial Infections
Le Kremlin-Bicêtre, France
View Trial DetailsLinezolid Dosing Strategies in Drug-Resistant TB
NCT05007821
Actinomycetales Infections, Bacterial Infections
Gaborone, South-East District, Botswana
View Trial Details